In triple-negative breast cancer, therapeutic response to carboplatin and docetaxel is similar. However, carboplatin therapy is superior to docetaxel in patients with germline BRCA1 or BRCA2 mutations, but ‘BRCAness’ does not predict sensitivity to carboplatin.
- Ana C. Garrido-Castro
- Eric P. Winer
